Q: How did you become interested in the clinical interpretation of next-generation sequencing data?

 

A: During my residency in Clinical Pathology, the power of next-generation DNA sequencing was readily apparent to me. Just as obvious was the limitation of fully utilizing the technology at a large scale due to challenges in efficiently and accurately analyzing these data for clinical purposes. Genomenon – from a Greek word meaning “born out of need” – began as my reaction to a lack of commercially available tools to help facilitate genomic analysis. My research in interpreting the genomes of hematopoietic malignancies to uncover their genetic cause was a perfect testing environment for some of the data-mining and organization techniques being used by Mastermind.

Q: What was your experience as a molecular pathologist at the University of Michigan when you had to search for disease, gene and variant relationships?

 

A: Two-fold. In many circumstances, the variant was well-known as a pathogenic variant but more detailed information was needed to address the specific clinical circumstance of the individual patient – things like identifying the most appropriate therapy for a variant in a particular disease context or determining whether the given variant had ever been seen in a specific clinical context. In a second case, when the variant was an unusual or otherwise less well-characterized variant, simply determining whether the variant had ever been published before, and if so where, how many times, in what disease contexts and with what clinical annotations, were the primary questions that needed to be addressed. In both circumstances, this discovery process relied heavily on information in the primary literature and invariably the process of manually finding and organizing the evidence was much more time-consuming and idiosyncratic than actually interpreting the results. I recognized that each time I consulted the literature, the same types of questions were asked. The inspiration behind founding Genomenon was when I recognized that much of this work could be automated and a comprehensive set of questions could be asked and answered up-front and at a massive scale.

Q: What are the challenges facing clinical interpretation of NGS data today?

 

A: Reproducibility of interpretation is the biggest challenge we face as clinicians. There are guidelines that are emerging to help compel order and regularity to the process but this is only effective when everyone is working with the same set of evidence. Efforts to organize a comprehensive dataset of clinically meaningful information for each individual variant face the challenge of doing this work at the massive scale demanded by the complexity and quantity of the data. These are the challenges that the Mastermind Genomic Search Engine, Genomenon’s first product, is addressing. It does this by collecting, organizing and presenting information at the variant level through a comprehensive data aggregation process predicated on the primary evidence in the medical literature.

Q: What are the benefits of Genomenon’s new evidence-based blood cancer panel?

 

A: One of the interesting facets of using NGS technology in Molecular Diagnostics is the ability to sequence many more genes on a single assay than was previously possible. This has lead to the promulgation of many dozens of disease-focused and more comprehensive diagnostic gene panels with a large number of biomarkers. One unforeseen challenge that arises as a result is the heterogeneity of each of these panels that are purporting to test for variants in the same disease or diseases. Using the data in Mastermind, we were able to automatically develop the first ever evidence-based list of candidate biomarkers for a disease category – hematopoietic malignancy. We published this cancer panel with all the evidence to demonstrate how biomarkers can be automatically identified at scale based on the evidence found in the scientific literature. This way, the inclusion or exclusion of a biomarker – whether a gene or a variant – can be predicated on the evidence supporting the usefulness of the gene or variant from the primary data, eliminating the subjectivity and inefficiency of a previously laborious and manual process.

Q: Can you give an example of how Genomenon’s Mastermind knowledge-base can improve cancer patient outcomes?

 

A: There are two ways Mastermind improves patient outcomes – both individual and collectively. For the individual, providing immediate and well-organized access to information in the medical literature will streamline the efficiency of the manual variant curation process. This is useful in bolstering more wide-spread use of defined guidelines for variant interpretation and promoting increased reproducibility of interpretations across institutions and molecular diagnosticians. In terms of improving patient outcomes collectively, having the comprehensive data made available to researchers allows for deeper and more immediate insight into the landscape of disease-gene and disease-gene-variant relationships that are otherwise difficult to see when examining individual studies or individual disease-relationships. Mastermind is being used in research to highlight these affinities and allow cancer researchers to ask questions more globally than previously possible.

Q: What are the complex challenges that the field of diagnostic genomics will face in the next five years?

 

A: With the ability to sequence more and more individuals in a greater variety of clinical scenarios, we are poised to controvert some long-held beliefs about genetic variation and the development of disease. These new discoveries will begin to challenge current diagnostic, and treatment paradigms. As an example, the discovery of a number of presumptive pathogenic variants discovered at a low-level in disease-free individuals will make much earlier interventions possible but it will also require clinicians to make a determination of which patients will in fact go on to develop disease and which may require enhanced surveillance.

Q: What advice can you give to young scientists considering an academic research career?

 

A: Keep an open mind. During your academic training, there will be the tendency to only see your successes measured by your publication record. In my case, I had successful outcomes from both my graduate training and post-doctoral work. During the course of the latter, I recognized that there were ways to advance a field from outside of academia that had the potential to make bigger and faster change than would typically be afforded from a conventional professorship. I recognized the benefit of effectuating change outside of academia in the private sector. Acceleration of the initial Human Genome Sequencing Project at the hands of Craig Venter and Celera proved that genome sequencing was possible at a much faster pace. This was followed by dramatic advances in efficiency and cost-effectiveness of DNA sequencing at scale afforded by technical revolutions in private companies such as Roche and Illumina which proved that genome sequencing was plausible. Our goal at Genomenon is to make genome sequencing practical by eliminating the final barrier to wide-spread adoption – accurate, efficient and reproducible genome interpretation.

Interview with Dan Rhodes from Strata Oncology

Q: What need is Strata Oncology addressing?

Despite substantial advances in precision oncology, the majority of advanced cancer patients still do not benefit from comprehensive tumor molecular profiling or precision therapy trials.

Read More

Interview with Lisa McLaughlin from Workit Health

Q: What need is Workit Health addressing?

Drug overdoses killed more Americans last year than were lost during the entire Vietnam War (69,000).

Read More

Interview with Olivier Elemento from Weill Cornell Medicine

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

I direct the Englander Institute for Precision Medicine, an Institute that focuses on using genomics and informatics to make medicine more individualized.

Read More

Interview with Dr. Dunnenberger from NorthShore University HealthSystem

Q: What patient population is NorthShore University HealthSystem serving and which services are you specializing in?

NorthShore is a four hospital community health system with over 100 outpatient medical offices.

Read More

How Artificial Intelligence (AI) Will Potentiate Individualized Medicine

We had the chance to sit down with Dr. Topol to hear his thoughts on big data, digital health, sensors, and artificial intelligence, some of the newest precision medicine technologies.

Read More

Interview with Jennifer Kloke from Ayasdi

Q: What need is Ayasdi addressing?

Ayasdi is pioneering the application of AI to value-based care by targeting two of the most complex problems in healthcare: population risk stratification and clinical variation management.

Read More

Q&A with Eric Topol, Executive Vice President, Scripps Research Institute

Dr. Eric Topol, voted by Modern Healthcare as the most influential physician executive in the United States, shared his thoughts on why people should own and control their own data.

Read More

CMS to Approve Coverage of NGS-based Cancer Testing | Big Pharma’s Response & The effect on PM

Why this is a Big Deal? As we know, private insurers follow suit once Medicare makes a decision such as this. This portends well for genetic testing to become routine standard of care for patients with advanced cancers.

Read More

Q&A with Mickey Kertesz, Chief Executive Officer, Karius

Q: Tell us a little bit about Karius – what problem(s)/need(s) are you trying to address and what technology is behind it to achieve this?

Read More

Join PMWC 2018 Michigan This June to Learn More about How the Modulation of the Epigenome Increases the Risk for Type 2 Diabetes

Dr. Michael Boehnke (University of Michigan) – who pioneered large-scale studies identifying genetic risk in diabetes and bipolar disorder – shared with us some recent insights about recent advances in exome and genome sequencing and their applications to better understand disease biology and etiology of psychiatric disorders

Read More

AI and Machine Learning in Healthcare – Not Just Hype Anymore

AI and machine learning has gotten a lot of attention over the last year, as it appears to be poised to become one of the biggest game changer in many industries, including the healthcare sector.

Read More

Q&A with Eric Lefkofsky, CEO of Tempus and Co-founder of Groupon

“Treating a cancer patient without the benefit of modern software is the same as driving at night without headlights”

Read More

PMWC Michigan – Big Data in Action: Data-Driven Insights in the Clinic

We are excited to launch the first Precision Medicine World Conference (PMWC) at the University of Michigan June 6-7, 2018.

Read More

Q&A with Susan A. Murphy, Harvard University

Q: Your lab develops experimental trial designs and data analysis methods for increasing the usefulness of mobile health interventions. Can you please give examples how these trials are being used in the areas of substance abuse, physical activity, or helping people quit smoking?

Read More

Q&A with Dr. Dara Richardson-Heron, Chief Engagement Officer, All of Us

Q: Your reputation for passion about engaging and empowering people precedes you. Can you please describe your role at the All of Us Research Program?

Read More
University of Michigan

The 14th Precision Medicine World Conference (PMWC) will take place at the University of Michigan on June 6-7, 2018. This conference coincides with University of Michigan’s launch of a new Precision Health research initiative that integrates U of M’s strengths in Medicine, Engineering, Pharmacy, and Public Health. (hyperlink) This initiative combines biomedical expertise, big data, and the social sciences enabling a comprehensive approach to providing patients with tailored health solutions.

To support the University of Michigan’s goal to bring together leading researchers from across the university and the country to springboard this new and exciting research initiative, PMWC and U-M have agreed that the campus is an optimal location for the next conference. This forum will showcase practical content that helps close the knowledge gap among different sectors, thereby catalyzing cross-functional fertilization and collaboration to benefit both University of Michigan and PMWC attendees.

The program will feature innovative technologies, and analyze the success of already thriving initiatives and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advances in precision medicine and cutting-edge strategies and solutions that are fundamentally changing how patients are treated. This is reflected in the Program Theme: “Big Data in Action: Data-driven Insights in the Clinic”.

Agenda highlights:

    • More than 35 sessions with 100+ thought-provoking, insightful talks that cover all facets of precision medicine
    • Two tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • Changing Pharmacogenomics
    • Community Setting Challenges
    • Patient Issues and Challenges
    • Legal and Ethical Issues
    • Integrating genomic data into EMRs
    • Emerging Technologies
    • Personalized Health Care Delivery
    • Personalized Modeling of Precision Health
    • NIH’s All of Us Study
    • Big Data in Action
    • Opioid Precision Health
    • Neurosciences
    • Big Data in the Clinic
    • Wellness and Aging
    • Epigenetics and Aging
    • Precision Cancer Therapy
    • Data Sharing in Translational Medicine
    • Economic and Socio-political Issues

The 14th Precision Medicine World Conference (PMWC) will take place at the University of Michigan on June 6-7, 2018. This conference coincides with University of Michigan’s launch of a new Precision Health research initiative that integrates U of M’s strengths in Medicine, Engineering, Pharmacy, and Public Health. (hyperlink) This initiative combines biomedical expertise, big data, and the social sciences enabling a comprehensive approach to providing patients with tailored health solutions.

To support the University of Michigan’s goal to bring together leading researchers from across the university and the country to springboard this new and exciting research initiative, PMWC and U-M have agreed that the campus is an optimal location for the next conference. This forum will showcase practical content that helps close the knowledge gap among different sectors, thereby catalyzing cross-functional fertilization and collaboration to benefit both University of Michigan and PMWC attendees.

The program will feature innovative technologies, and analyze the success of already thriving initiatives and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advances in precision medicine and cutting-edge strategies and solutions that are fundamentally changing how patients are treated. This is reflected in the Program Theme: “Big Data in Action: Data-driven Insights in the Clinic”.

Agenda highlights:

    • More than 35 sessions with 100+ thought-provoking, insightful talks that cover all facets of precision medicine
    • Two tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
        • Changing Pharmacogenomics
        • Community Setting Challenges
        • Patient Issues and Challenges
        • Legal and Ethical Issues
        • Integrating genomic data into EMRs
        • Emerging Technologies
        • Personalized Health Care Delivery
        • Personalized Modeling of Precision Health
        • NIH’s All of Us Study
        • Big Data in Action
        • Opioid Precision Health
        • Neurosciences
        • Big Data in the Clinic
        • Wellness and Aging
        • Epigenetics and Aging
        • Precision Cancer Therapy
        • Data Sharing in Translational Medicine
        • Economic and Socio-political Issues

 

Confirmed thought leaders include:

Lee Hood

Lee Hood

Chief Science Officer, Providence Health

Eric Topol

Eric Topol

Chief Academic Officer, Scripps Health

Francis Collins

Francis Collins

Director of the National Institutes of Health (NIH)

Vicki L. Ellingrod

Vicki L. Ellingrod

Ass. Dir., Michigan Inst. for Clinical & Health Research

Goncalo Abecasis

Goncalo Abecasis

Chair, Department of Biostatistics, UM

Jeffrey Leiden

Jeffrey Leiden

Chairman, President and CEO, Vertex

Matthias Kretzler

Matthias Kretzler

Professor, Nephrology & Internal Medicine, UM

Arul Chinnaiyan

Arul Chinnaiyan

Professor of Pathology, Medical Institute, UM

David Ginsburg

David Ginsburg

Prof., Human Genetics; Investigator, UM

Steve Nelson

Steve Nelson

Chief Executive Officer, UnitedHealthcare

Gil Omenn

Gil Omenn

Dir., Comput. Med. & Bioinformatics Center, UM

Eric Lefkofsky

Eric Lefkofsky

Founder and CEO, Tempus

Steven Leeder

Steven Leeder

Dir., Clin. Pharmacology Children’s Mercy Hospital,(CMH)

Ariella Shikanov

Ariella Shikanov

Assistant Professor, Biomedical Engineering, UM

Lawrence Corey

Lawrence Corey

Presi. & Dir. Emeritus, Fred Hutch Cancer Research Cent.

Amir Dan Rubin

Amir Dan Rubin

President and CEO, One Medical

Isaac (Zac) Kohane

Isaac (Zac) Kohane

Professor of Pediatrics, Harvard University

Sachin Kheterpal

Sachin Kheterpal

Associate Professor, Anesthesiology, UM

Event Highlights

When
June 6, 2018 8:00am to June 7, 2018 5:00pm
Where
Ross School of Business
701 Tappan Ave
Ann Arbor, MI 48109
Cost
$774 by May 2nd, 2018

Registration: PMWC Conferences

Michigan June 6-7, 2018

First PMWC In Midwest
2 Track Speaker Lineup
Access to the exhibition
Breakfast & lunch refreshments
Award Reception

Having Trouble Registering? We accept all major credit cards. Select 'PayPal Check out' and press 'Pay with Debit or Credit Card'.
Click here or call (650)-961-8877 to contact the PMWC Team for Help or to ask about the academic rate.